Compare Charles River Laboratories Intl. Inc (CRL) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.17. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| CRL | VCIT | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | Fixed Income |
52-Week High | $282.00 | $84.82 |
52-Week Low | $145.57 | $81.07 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.20 with a slight 0.16% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators are neutral. The fund maintains consistent monthly dividend distributions, with recent payouts around $0.33-$0.34. News highlights VCIT's competitive 0.03% expense ratio and approximately 5% yield compared to peers like iShares corporate bond ETFs, emphasizing its cost efficiency for income-focused investors.
The outlook for VCIT is mixed, offering attractive income through corporate bond exposure but facing interest rate sensitivity. Opportunities include high relative yield and low fees, while risks involve corporate credit deterioration and Fed policy shifts. Investors should weigh yield advantages against potential volatility from economic changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
